Cerity Partners LLC Acquires 18,414 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cerity Partners LLC boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 128.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,757 shares of the specialty pharmaceutical company's stock after buying an additional 18,414 shares during the period. Cerity Partners LLC owned approximately 0.05% of Jazz Pharmaceuticals worth $3,650,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. CWA Asset Management Group LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $3,197,000. Swedbank AB acquired a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $106,936,000. Pacer Advisors Inc. grew its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after buying an additional 278,465 shares during the period. Philip James Wealth Mangement LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $830,000. Finally, Victory Capital Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 42.7% during the 2nd quarter. Victory Capital Management Inc. now owns 205,492 shares of the specialty pharmaceutical company's stock valued at $21,932,000 after acquiring an additional 61,458 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 over the last ninety days. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Down 0.9 %

Jazz Pharmaceuticals stock traded down $1.05 during midday trading on Friday, hitting $121.59. 286,839 shares of the stock were exchanged, compared to its average volume of 675,459. The business's 50-day moving average price is $114.87 and its 200-day moving average price is $111.12. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of 17.13, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Analyst Ratings Changes

JAZZ has been the subject of a number of research reports. Royal Bank of Canada raised their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an "outperform" rating in a report on Wednesday, October 23rd. HC Wainwright restated a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC reaffirmed a "buy" rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Piper Sandler reiterated an "overweight" rating and issued a $163.00 price target (down previously from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $175.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.